Summary
Synopsys Inc. reported solid revenue growth for the second quarter of fiscal year 2011, with total revenue increasing by 16% year-over-year to $393.7 million. This growth was driven by an increase in time-based license revenue and professional services revenue, bolstered by contributions from prior year acquisitions. The company also achieved a significant increase in net income, rising 105% to $81.1 million, largely attributed to a one-time tax benefit of $32.8 million resulting from a final IRS settlement for fiscal years 2006-2009. Despite increased operating expenses related to headcount growth from acquisitions and employee costs, the company maintained its focus on profitability and operational efficiency. Synopsys ended the quarter with a strong liquidity position, holding $840.5 million in cash, cash equivalents, and short-term investments, with no outstanding borrowings under its credit facility.
Financial Highlights
50 data points| Revenue | $393.67M |
| Cost of Revenue | $86.03M |
| Gross Profit | $307.64M |
| R&D Expenses | $123.17M |
| Operating Expenses | $255.96M |
| Operating Income | $51.69M |
| Net Income | $81.11M |
| EPS (Basic) | $0.55 |
| EPS (Diluted) | $0.53 |
| Shares Outstanding (Basic) | 148.46M |
| Shares Outstanding (Diluted) | 152.59M |
Key Highlights
- 1Total revenue increased by 16% to $393.7 million for the three months ended April 30, 2011, compared to $338.1 million in the prior year period.
- 2Net income saw a substantial increase of 105% to $81.1 million, primarily due to a $32.8 million tax benefit from an IRS settlement.
- 3Time-based license revenue, the company's largest revenue stream, grew by 10% year-over-year.
- 4Maintenance and service revenue increased by 36% to $49.9 million, driven by professional services contracts from recent acquisitions.
- 5Operating expenses increased, reflecting higher personnel costs and expenses related to prior year acquisitions.
- 6The company maintained a strong balance sheet with $840.5 million in cash, cash equivalents, and short-term investments as of April 30, 2011.
- 7Synopsys continues to repurchase shares, with $80.3 million remaining available under its stock repurchase program as of the end of the quarter.